Gadolinium-Based Contrast Agents – Deposition in the brain

17 Aug Gadolinium-Based Contrast Agents – Deposition in the brain

The following pharmaceutical companies: AXIM Pharmaceuticals (Pty) Ltd, Guerbet South Africa (Pty) Ltd and GE Healthcare SA in collaboration with South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the safety information regarding the risk of gadolinium brain deposition following the...

17 Aug Dolutegravir – Risk of neural tube defects

ViiV Healthcare would like to inform you of a potential safety issue which has been brought to our attention by the Principal Investigator of the above study conducted in Botswana. The potential safety issue is related to Neural Tube Defect (NTD) cases in infants born...

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACE inhibitors / Angiotensin Receptor Blockers (ARBs) and fluoroquinolones....

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEIs / Angiotensin Receptor blockers (ARBs) and fluoroquinolones....

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) Angiotensin receptor blockers (ARBs) and fluoroquinolones....

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEls / Angiotensin receptor blockers (ARBs) and fluoroquinolones. ...

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers – 1 August 2019

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin-converting enzyme inhibitors (ACEls) / Angiotensin receptor blockers (ARBs) and fluoroquinolones.

Date updated

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa

Notification of an important new warning with treatment of patients with anti phospholipid syndrome (APS) and the use Pradaxa: Increased risk of thrombo-embolic events ...

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto

Important safety information on the treatment of patients with antiphospholipid syndrome (APS) and the use of rivaroxaban (Xarelto®) Possible increased risk for recurrent thrombotic events ...

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis

Pfizer Laboratories (Pty) Ltd, in agreement with South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the following changes to the Professional Information of Eliquis (apixaban). ...